Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2A, Open Label Dose Escalation and Expansion Study of Orally Administered CA-4948 as a Monotherapy in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

NCT04278768 is registered in ClinicalTrials.gov with Curis, Inc. as lead sponsor.

NCT NCT04278768
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04278768 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2A, Open Label Dose Escalation and Expansion Study of Orally Administered CA-4948 as a Monotherapy in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Lead sponsor
Curis, Inc.
Phase
Phase 1/2
Overall status
Suspended
Start date
July 6, 2020
Completion date
April 1, 2026
Enrollment
366 (estimated)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

acute myelogenous leukemia, myelodysplastic syndrome